SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sepracor-Looks very promising
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
10280 115 0 SEPR
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
8655Thanks Jon - that's very encouraging. Do you have a TRx share number for theBiomaven-8/8/2005
8654Solid week for L but weak for X as trough is elongating out this year. For L, wRobohogs-8/8/2005
8653For fun. Sepr pipeline chart from 5 years ago, looks like 5 of 16 made the graderkrw-8/6/2005
8652<i>TRx share had been trailing new share by just over 3% but the spread isBiomaven-8/3/2005
8651XenoPort Eyeing Restless Leg Syndrome Phase III [Some information on the RLS maIcebrg-8/3/2005
8650Sanofi-Aventis Reject May Be Sepracor's First $1 Billion Drug Aug. 3 (BloomIcebrg-8/3/2005
8649Market share as defined by JPM (includes Ambien, Lunesta, Sonata, restoril, prosRobohogs-8/2/2005
8648Sepracor Adopts ''Guiding Principles'' for Consumer Advertising Iamarangerboy-8/2/2005
8647Everyone has his own share numbers - some add benzos and some do not. Looking aRobohogs-8/1/2005
8646<i>~40% vs. 65% industry average - actually unbelievable for this stage<Biomaven-8/1/2005
8645thanks Jon!!!Iamarangerboy-8/1/2005
8644Weekly data came in a bit better than my interpretation from a graph. New highsRobohogs-8/1/2005
8643"I agree that Lunesta spend is much higher than 1% (of course) but after saRocky9-7/31/2005
8642rkrw, I am just stating what was in the table next to the article - the top tenHarold Engstrom-7/31/2005
8641So lunesta will be getting to $10B in annual revenues to equate $100M in ad spenrkrw-7/31/2005
8640Right. But that still puts advertising specifically at 1% of revenue and only 3Harold Engstrom-7/31/2005
8639Typical pharma sg&a these days is > 30% of revenues, for pfe more than dorkrw-7/31/2005
8638I think the article is self-defeating. The point of the article is to blast theHarold Engstrom-7/31/2005
8637With advertising under siege, drug makers rethink their marketing message Push iIcebrg-7/31/2005
8636thanks for the input Rocky and Jon.... appreciate the insight into doc experiencIamarangerboy-7/29/2005
8635I have seen one report that had a graph of the numbers through early week this wRobohogs-7/28/2005
8634Clearly noone has it. The weekly number will not be available to anyone until MRocky9-7/28/2005
8633don't everyone answer at once.... (eom)Iamarangerboy-7/28/2005
8632anyone with access to the scrip data of 7/22 week?Iamarangerboy-7/27/2005
8631My copay is $50 vs $30 for ambien. Personally I think it is worth the differencebarkdog-7/27/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News